ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0645

Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis

Samir Patel1, Zijing Yang1, deepak Nagra1, Maryam Adas2, Mark Russell1, Sam Norton1, Chris Wincup3, James Galloway4, Kate Bramham2 and Patrick Gordon5, 1King's College London, London, England, United Kingdom, 2King's College London, London, United Kingdom, 3King's College Hospital, London, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 5nhs, London, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Epidemiology, Mortality, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations and associated with premature mortality. Survival is thought to vary across ethnicities in patients with SLE; however, there has not been a comprehensive review or meta-analysis demonstrating this. Thus, we aimed to investigate the association between ethnicity and mortality in patients with SLE.

Methods: We performed a systematic literature search of the databases MEDLINE, Embase and the Cochrane Library, from inception to 31 December 2023. Search terms included systemic lupus erythematosus, ethnicity, race, mortality and synonyms. Study eligibility criteria were cohort studies and trials that reported on the mortality of adults >16 years old with SLE. We used a pairwise meta-analysis to determine the pooled odds ratio of death for those from Black, Asian, Hispanic or Indigenous ethnic groups compared to those of White ethnicity, recognising that non-White ethnicities represented underserved populations.

Results: Forty studies, comprising 92,079 patients with SLE were included (Figure 1). Overall, non-White ethnicity was significantly associated with death compared to White ethnicity (OR 1.15 [95% CI: 1.01-1.32]; Figure 2). On subgroup analysis, mortality was higher in Black patients (OR 1.30 [95% CI: 1.16-1.46]) and Indigenous patients (OR 1.45 [95% CI: 1.10-1.89]), whilst Asian and Hispanic patients showed no significant differences compared to White patients with SLE (Table 1). Meta-regression found no associations between study effect size, length of follow-up or mid-year point. The association between ethnicity and mortality in patients with SLE did not appear to change over time. Sixty-five percent of included studies were conducted in the United States of America (USA) and when excluded, the significant difference in mortality between Black and White individuals with SLE was no longer seen (OR 0.84 [95% CI: 0.54-1.31]; Table 1).

Conclusion: Patients with SLE from Black or Indigenous ethnicities had higher mortality than those from White ethnicities. This could be driven by several complex and diverse factors such as structural racism, associated socioeconomic deprivation, healthcare accessibility, differing cultural beliefs or more severe SLE phenotypes in these ethnic groups. However, on sensitivity analyses we observed inconsistencies between USA and non-USA cohorts regarding the association of Black ethnicity and mortality, though a scarcity of data outside of the USA was noted. Recent national data from the USA described higher mortality in the general Black and Indigenous American population compared to the White American population, suggesting a wider systemic issue which may be reflected in, but not limited to, patients with SLE. Until more generalisable data outside of the USA are available, we promote caution in the use of ethnicity as a risk factor for mortality.

Supporting image 1

Figure 1. PRISMA flow diagram of literature search and study inclusion

Supporting image 2

Figure 2. Association between ethnicity and mortality in patients with SLE. White ethnicity was used as the reference group for all comparisons. Weights are from random-effects analyses. Bars indicate 95% confidence intervals (CI).

Supporting image 3

Table 1. Pooled odds ratio (OR) of death in patients with SLE across ethnicities and country. CI: confidence intervals.


Disclosures: S. Patel: None; Z. Yang: None; d. Nagra: None; M. Adas: None; M. Russell: AbbVie, Biogen, Lilly, Galapagos, Menarini, UCB, Viforpharma, 6, Sandoz UK, 5; S. Norton: None; C. Wincup: Versus Arthritis, Lupus UK, Astrazeneca and British Society for Rheumatology, 5; J. Galloway: AbbVie, 6, AstraZeneca, 5, Galapagos, 2, 6, Janssen, 2, 5, 6, Lilly, 2, 6, Pfizer, 2, 5, 6, UCB, 6; K. Bramham: None; P. Gordon: Alexion, 12, Primary investigator at King's college hospital for the NCT04999020 study (ALXN1210-DM-310). No personal payment, Argenx, 12, PI at King's College Hospital for study ARGX-113-2007 and Study ARGX-113-2011, Bristol-Myers Squibb(BMS), 12, POETYK SLE study (NCT05620407), Chief investigator for UK and site PI at King's College Hospital London for this study ., Celltrion Healthcare, 12, Funded to attend EULAR convergence in 2023, Eli Lilly, 12, PI at King's College Hospital for MOJAK, funded by Eli Lilly with University of Manchester as the Sponsor. Termination date aproximate, Galapagos, 1, 2, 12, Chief investigator in UK for Galarisso study (NCT05695950).

To cite this abstract in AMA style:

Patel S, Yang Z, Nagra d, Adas M, Russell M, Norton S, Wincup C, Galloway J, Bramham K, Gordon P. Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/mortality-and-ethnicity-in-adults-with-systemic-lupus-erythematosus-a-systematic-literature-review-and-meta-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-and-ethnicity-in-adults-with-systemic-lupus-erythematosus-a-systematic-literature-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology